Cargando…

Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease

INTRODUCTION: Parathyroid hormone-lowering responses after administration of three different therapies capable of raising serum total 25-hydroxyvitamin D (25OHD) were evaluated in patients with secondary hyperparathyroidism (SHPT), vitamin D insufficiency (VDI), and stage 3 or 4 chronic kidney disea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strugnell, Stephen A., Csomor, Philipp, Ashfaq, Akhtar, Bishop, Charles W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368011/ https://www.ncbi.nlm.nih.gov/pubmed/37497207 http://dx.doi.org/10.1159/000529523

Ejemplares similares

Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism
por: Bishop, Charles W., et al.
Publicado: (2022)

Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients
por: Germain, Michael J., et al.
Publicado: (2022)

Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis
por: Cozzolino, Mario, et al.
Publicado: (2021)

Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease
por: Friedl, Claudia, et al.
Publicado: (2017)

Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients with COVID-19
por: Mazziotti, G., et al.
Publicado: (2021)

LBSAT229 Extended-release Calcifediol Effectively Raised 25-hydroxyvitamin D In CKD Despite Obesity
por: Strugnell, Stephen A, et al.
Publicado: (2022)

Association of Vitamin D and secondary hyperparathyroidism with anemia in diabetic kidney disease
por: Sonkar, Satyendra Kumar, et al.
Publicado: (2018)

Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future
por: Brandenburg, Vincent, et al.
Publicado: (2022)

LBSAT131 Extended-release Calcifediol Reduced Ipth And Normalized 1,25-dihydroxyvitamin D In Esrd.
por: Ashfaq, Akhtar, et al.
Publicado: (2022)

Exacerbation of Hyperparathyroidism, Secondary to a Reduction in Kidney Function, in Individuals With Vitamin D Deficiency
por: Daimon, Makoto, et al.
Publicado: (2020)

Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency
por: Elbers, Laura P B, et al.
Publicado: (2018)

Factors in nephrologists’ decision to treat pre-dialysis CKD patients with vitamin D insufficiency and SHPT: A discrete choice experiment
por: Reddy, Anand C., et al.
Publicado: (2023)

Vitamin D insufficiency and deficiency in children with chronic kidney disease
por: Kari, Jameela Abdulaziz, et al.
Publicado: (2012)

The Emerging Role of Nutritional Vitamin D in Secondary Hyperparathyroidism in CKD
por: Lu, Chien-Lin, et al.
Publicado: (2018)

Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism
por: Shigematsu, Takashi, et al.
Publicado: (2022)

Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: a meta-analysis
por: Bover, Jordi, et al.
Publicado: (2021)

Secondary hyperparathyroidism among Nigerians with chronic kidney disease
por: Gimba, Zumnan M, et al.
Publicado: (2018)

Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management
por: Habas, Elmukhtar, et al.
Publicado: (2021)

Unmasking of primary hyperparathyroidism by Vitamin D therapy
por: Bala, S., et al.
Publicado: (2015)

Sagliker Syndrome in a Patient with Secondary Hyperparathyroidism and Chronic Renal Insufficiency: A Case Report
por: Shakeri, Sara, et al.
Publicado: (2018)

LBSAT230 Daily Variation In Serum Calcifediol In Japanese And Non-japanese Adults
por: Ashfaq, Akhtar, et al.
Publicado: (2022)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Parathyroid Cell Proliferation in Secondary Hyperparathyroidism of Chronic Kidney Disease
por: Naveh-Many, Tally, et al.
Publicado: (2020)

Vitamin D insufficiency and deficiency with stages of chronic kidney disease in an Asian population
por: Satirapoj, Bancha, et al.
Publicado: (2013)

Association of Secondary Hyperparathyroidism with Hemoglobin Level in Patients with Chronic Kidney Disease
por: Chutia, Happy, et al.
Publicado: (2013)

Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease
por: Rodríguez-Ortiz, María E., et al.
Publicado: (2020)

Secondary and Tertiary Hyperparathyroidism in Chronic Kidney Disease: An Endocrine and Renal Perspective
por: Chandran, Manju, et al.
Publicado: (2019)

Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease
por: Xu, Yang, et al.
Publicado: (2021)

Complications after radiofrequency ablation of hyperparathyroidism secondary to chronic kidney disease
por: Lin, Li-Ping, et al.
Publicado: (2023)

Outcomes of Secondary Hyperparathyroidism in Chronic Kidney Disease and the Direct Costs of Treatment
por: Joy, Melanie S., et al.
Publicado: (2007)

Vitamin D Insufficiency Risk Score for Screening for Vitamin D Insufficiency
por: Garg, Shobhit, et al.
Publicado: (2019)

Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
por: Wetmore, James B, et al.
Publicado: (2008)

Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2016)

Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease
por: Abbas, Fizza, et al.
Publicado: (2019)

The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation
por: Tabibzadeh, Nahid, et al.
Publicado: (2020)

Vitamin D and Hyperparathyroidism: The Lumleian Lecture 1981
por: Stanbury, S.W.
Publicado: (1981)

Extended-release calcifediol in stage 3–4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D
por: Cozzolino, Mario, et al.
Publicado: (2021)

Pin1 and secondary hyperparathyroidism of chronic kidney disease: gene polymorphisms and protein levels
por: Zhao, Yu, et al.
Publicado: (2016)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism
por: Yu, Longchuan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d9j89rp5eg5qpo59svu90s9itc